Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome.

Bemis LT, Robinson WA, McFarlane R, Buyers E, Kelly K, Varella-Garcia M, Mitchell JD, Franklin WA.

Lancet Oncol. 2007 Jun;8(6):559-60. No abstract available.

PMID:
17540308
2.

EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature.

Ricordel C, Labalette-Tiercin M, Lespagnol A, Kerjouan M, Dugast C, Mosser J, Desrues B, Léna H.

Lung Cancer. 2015 Jan;87(1):80-4. doi: 10.1016/j.lungcan.2014.11.005. Epub 2014 Nov 20. Review.

PMID:
25433984
3.

EGFR-mutated lung cancer in Li-Fraumeni syndrome.

Michalarea V, Calcasola M, Cane P, Tobal K, Izatt L, Spicer J.

Lung Cancer. 2014 Sep;85(3):485-7. doi: 10.1016/j.lungcan.2014.06.017. Epub 2014 Jun 30.

PMID:
25047674
4.

Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y.

Med Oncol. 2013;30(3):645. doi: 10.1007/s12032-013-0645-1. Epub 2013 Jun 25.

PMID:
23797772
5.

Multiple synchronous lung cancers and atypical adenomatous hyperplasia in Li-Fraumeni syndrome.

Nadav Y, Pastorino U, Nicholson AG.

Histopathology. 1998 Jul;33(1):52-4.

PMID:
9726049
6.

FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma.

Putora PM, Früh M, Müller J.

Respirology. 2013 May;18(4):734-5. doi: 10.1111/resp.12083.

PMID:
23489365
7.

Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule.

Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, Nakatomi K, Fujino S, Hayashi T, Nakamura Y, Tsukamoto K, Kohno S.

Lung Cancer. 2008 Apr;60(1):136-40. Epub 2007 Sep 24.

PMID:
17889960
8.

[Germline tp53 neomutation in a patient with Li-Fraumeni syndrome and pancreatic adenocarcinoma].

Lefrou L, Godart B, de Muret A, Scotto B, Dorval E.

Gastroenterol Clin Biol. 2006 Mar;30(3):484-6. French. No abstract available.

9.

Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation.

Cho WC, Chow AS, Au JS.

Eur J Cancer. 2009 Aug;45(12):2197-206. doi: 10.1016/j.ejca.2009.04.039. Epub 2009 Jun 1.

PMID:
19493678
11.

Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.

Haneda H, Sasaki H, Shimizu S, Endo K, Suzuki E, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

Lung Cancer. 2006 Apr;52(1):47-52. Epub 2006 Feb 28.

PMID:
16503085
12.

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, Kopper L, Schwab R, Petak I.

J Mol Diagn. 2008 Mar;10(2):160-8. doi: 10.2353/jmoldx.2008.070125. Epub 2008 Feb 7.

13.

Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?

Inamura K, Ninomiya H, Ishikawa Y, Matsubara O.

Arch Pathol Lab Med. 2010 Jan;134(1):66-72. doi: 10.1043/2008-0586-RAR1.1. Review.

PMID:
20073607
14.

Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

Yatabe Y, Matsuo K, Mitsudomi T.

J Clin Oncol. 2011 Aug 1;29(22):2972-7. doi: 10.1200/JCO.2010.33.3906. Epub 2011 Jul 5.

PMID:
21730270
15.

Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.

Rosell R, Felip E, Reguart N, Moran T.

Future Oncol. 2005 Jun;1(3):319-22. Review. No abstract available.

PMID:
16556005
16.

Spectrum of EGFR mutation in lung adenocarcinoma in Morocco.

Elghissassi I, Errihani H.

J Thorac Oncol. 2013 Dec;8(12):e115-6. doi: 10.1097/JTO.0000000000000023. No abstract available.

17.

Spectrum of EGFR mutation in lung adenocarcinoma in Morocco.

Ismaili N, Belbaraka R.

J Thorac Oncol. 2013 Dec;8(12):e114-5. doi: 10.1097/JTO.0000000000000014. No abstract available.

18.

Lung carcinoma morphology or mutational profile: that is the question.

Dacic S.

Arch Pathol Lab Med. 2011 Oct;135(10):1242-3. doi: 10.5858/arpa.2011-0223-ED. No abstract available.

PMID:
21970476
19.

Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.

Tomonaga N, Nakamura Y, Yamaguchi H, Ikeda T, Mizoguchi K, Motoshima K, Doi S, Nakatomi K, Iida T, Hayashi T, Nagayasu T, Tsukamoto K, Kohno S.

Clin Lung Cancer. 2013 Sep;14(5):521-6. doi: 10.1016/j.cllc.2013.04.005. Epub 2013 Jun 17.

PMID:
23786997
20.

Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.

Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, Kim JH, Chung KY, Kim SK, Chang J.

Cancer. 2007 Feb 1;109(3):581-7.

Supplemental Content

Support Center